Detalhe da pesquisa
1.
A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.
Invest New Drugs
; 39(5): 1284-1297, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33852104
2.
Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma.
Neurology
; 101(24): e2472-e2482, 2023 Dec 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37652699
3.
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
J Clin Oncol
; 38(1): 1-10, 2020 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31682550